| Nonviral delivery of self-amplifying RNA vaccines AJ Geall, A Verma, GR Otten, CA Shaw, A Hekele, K Banerjee, Y Cu, ... Proceedings of the National Academy of Sciences 109 (36), 14604-14609, 2012 | 716 | 2012 |
| Preclinical and clinical demonstration of immunogenicity by mRNA vaccines against H10N8 and H7N9 influenza viruses K Bahl, JJ Senn, O Yuzhakov, A Bulychev, LA Brito, KJ Hassett, ME Laska, ... Molecular Therapy 25 (6), 1316-1327, 2017 | 659 | 2017 |
| Optimization of lipid nanoparticles for intramuscular administration of mRNA vaccines KJ Hassett, KE Benenato, E Jacquinet, A Lee, A Woods, O Yuzhakov, ... Molecular Therapy-Nucleic Acids 15, 1-11, 2019 | 618 | 2019 |
| A cationic nanoemulsion for the delivery of next-generation RNA vaccines LA Brito, M Chan, CA Shaw, A Hekele, T Carsillo, M Schaefer, J Archer, ... Molecular Therapy 22 (12), 2118-2129, 2014 | 343 | 2014 |
| Efficient targeting and activation of antigen-presenting cells in vivo after modified mRNA vaccine administration in rhesus macaques F Liang, G Lindgren, A Lin, EA Thompson, S Ols, J Röhss, S John, ... Molecular Therapy 25 (12), 2635-2647, 2017 | 315 | 2017 |
| Rapidly produced SAM® vaccine against H7N9 influenza is immunogenic in mice A Hekele, S Bertholet, J Archer, DG Gibson, G Palladino, LA Brito, ... Emerging microbes & infections 2 (1), 1-7, 2013 | 252 | 2013 |
| Nucleic acid vaccines: prospects for non-viral delivery of mRNA vaccines RP Deering, S Kommareddy, JB Ulmer, LA Brito, AJ Geall Expert opinion on drug delivery 11 (6), 885-899, 2014 | 234 | 2014 |
| Commentary: acceptable levels of endotoxin in vaccine formulations during preclinical research LA Brito, M Singh Journal of pharmaceutical sciences 100 (1), 34-37, 2011 | 214 | 2011 |
| Novel approaches for vaccine development MS Gebre, LA Brito, LH Tostanoski, DK Edwards, A Carfi, DH Barouch Cell 184 (6), 1589-1603, 2021 | 206 | 2021 |
| Impact of lipid nanoparticle size on mRNA vaccine immunogenicity KJ Hassett, J Higgins, A Woods, B Levy, Y Xia, CJ Hsiao, E Acosta, ... Journal of Controlled Release 335, 237-246, 2021 | 204 | 2021 |
| Vaccine adjuvant formulations: a pharmaceutical perspective LA Brito, P Malyala, DT O’Hagan Seminars in immunology 25 (2), 130-145, 2013 | 196 | 2013 |
| Self-amplifying mRNA vaccines LA Brito, S Kommareddy, D Maione, Y Uematsu, C Giovani, FB Scorza, ... Advances in genetics 89, 179-233, 2015 | 191 | 2015 |
| Designing and building the next generation of improved vaccine adjuvants LA Brito, DT O'Hagan Journal of Controlled Release 190, 563-579, 2014 | 188 | 2014 |
| Rational design of small molecules as vaccine adjuvants TYH Wu, M Singh, AT Miller, E De Gregorio, F Doro, U D’Oro, ... Science translational medicine 6 (263), 263ra160-263ra160, 2014 | 187 | 2014 |
| Potent immune responses in rhesus macaques induced by nonviral delivery of a self-amplifying RNA vaccine expressing HIV type 1 envelope with a cationic nanoemulsion WM Bogers, H Oostermeijer, P Mooij, G Koopman, EJ Verschoor, D Davis, ... The Journal of infectious diseases 211 (6), 947-955, 2015 | 180 | 2015 |
| Induction of broad-based immunity and protective efficacy by self-amplifying mRNA vaccines encoding influenza virus hemagglutinin M Brazzoli, D Magini, A Bonci, S Buccato, C Giovani, R Kratzer, V Zurli, ... Journal of virology 90 (1), 332-344, 2016 | 156 | 2016 |
| Overview of vaccine adjuvants: introduction, history, and current status RR Shah, KJ Hassett, LA Brito Vaccine adjuvants: methods and protocols, 1-13, 2017 | 139 | 2017 |
| Methods for making pharmaceutical formulations comprising microparticles with improved dispersibility, suspendability or wettability D Chickering, S Reese, S Narasimhan, J Straub, H Bernstein, D Altreuter, ... US Patent App. 10/955,261, 2005 | 137 | 2005 |
| Induction of robust B cell responses after influenza mRNA vaccination is accompanied by circulating hemagglutinin-specific ICOS+ PD-1+ CXCR3+ T follicular helper cells G Lindgren, S Ols, F Liang, EA Thompson, A Lin, F Hellgren, K Bahl, ... Frontiers in immunology 8, 1539, 2017 | 136 | 2017 |
| The impact of size on particulate vaccine adjuvants RR Shah, DT O'Hagan, MM Amiji, LA Brito Nanomedicine 9 (17), 2671-2681, 2014 | 122 | 2014 |
